GAD2 and paraneoplastic neurologic syndrome: The results are consistent with a previous observation, which found that 46.67% (7/15) of anti-GAD65-associated paraneoplastic neurological syndrome patients acquired clinical improvement or stability under various immunotherapy treatments, and amelioration occurred in only 4 thymic tumor patients, while only 1/6 of lung cancer patients was stable, and the rest were all deteriorated [7].